Here are three things to know:
1. The medical device company’s amendments constitute some of the following changes with its lenders:
• No interest will be charged on the loan’s outstanding balance under the credit facility between April 1 and Dec. 31.
• The fee due upon payment, prepayment or repayment of the loans’ principal amount under the credit facility increased from 1 percent to 2 percent.
2. Xtant issued warrants for 1.2 million shares of common stock at $0.01 per share, expiring Aug. 1.
3. The warrants were issued to OrbiMed Royalty Opportunities II and ROS Acquisition Offshore. Together, the two companies own an estimated 70 percent of Xtant’s outstanding common stock and are the sole holders of the company’s outstanding long-term debt under the credit facility.
More articles on devices:
Smith & Nephew to pay ConforMIS $10.5M in patent dispute settlement, licensing agreement: 4 key notes
3 things to know about Shukla Medical
Medtronic among leaders in sustainability: 3 notes
